



Executive Officer and Chief Scientific Officer of Callisto Pharmaceuticals, Inc. since May 2003. In July 2008, Dr. Jacob was named President and Acting Chief Executive Officer of Synergy Pharmaceuticals, a development stage company focused on drugs to treat gastrointestinal disorders and diseases. Dr. Jacob formerly served as Chief Scientific Officer of Synergy Pharmaceuticals Inc. from 1999 to 2003.

Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.

Dr. Jacob received his Ph.D. in biochemistry from the University of Wisconsin-Madison.

Dr. Jacob will serve on the Executive Committee and the Compensation Committee of the Board and will also serve as the Company's Secretary. The Agreement provides that the Company's Board will name an additional director to the Executive Committee, which currently consists of Dr. Kira Sheinerman, who is the Committee Chairperson, and Dr. Jacob. The Executive Committee, in addition to its other roles and responsibilities, will be involved with the Company's currently-ongoing search for a new chief executive officer.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 18, 2009

XENOMICS, INC.

/s/ Gary Anthony

-----

Gary Anthony

Vice President and Controller